-
Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine
Date last updated: 08/25/2021
-
Neuroscience Conferences
Date last updated: 07/13/2021
-
Cardiovascular & Metabolism Conferences
Date last updated: 05/13/2021
-
Oncology Conferences
Date last updated: 09/17/2021
-
Johnson & Johnson Statement on U.S. FDA Approval of Shelf Life Extension for Company’s COVID-19 Vaccine
Date last updated: 08/27/2021
-
Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in New England Journal of Medicine
Date last updated: 07/14/2021
-
Johnson & Johnson Statement on COVID-19 Vaccine (7/12)
Date last updated: 07/13/2021
-
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
Date last updated: 07/02/2021
-
Janssen COVID-19 Vaccine (Ad26.COV2.S) EUA Approval Press Release
Date last updated: 02/27/2021
-
SYMTUZA® (darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide) Dear Healthcare Professional Letter, December 2020
Date last updated: 12/23/2020
-
Data presented at American College of Rheumatology (ACR) 2020
Date last updated: 10/27/2020
-
Janssen Scientific Affairs, LLC announces the availability of the Population Health Management Resource Guide in partnership with NCQA
Date last updated: 10/09/2018
-
NCQA Partners with Janssen on a PHM Resource Guide for Health Care Organizations
Date last updated: 04/16/2018
